Overview

Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial

Status:
Recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
The trial of IV arginine therapy in children with Vaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) is designed to further knowledge on efficacy and safety of the therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Emory University
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)